Navigation Links
Orthopedic Development Corporation's TruFUSE(R) Procedure Tops 1,750 Patients in First Year
Date:9/24/2007

CLEARWATER, Fla., Sept. 24 /PRNewswire/ -- Orthopedic Development Corporation, parent company to minSURG Corporation announced today that over 1,750 patients have received the TruFUSE posterior fusion procedure since its introduction last year. TruFUSE, one of the first intermediate surgical solutions to treat intractable back pain, has been in limited distribution.

The TruFUSE technique uses two small cork-shaped dowels made of human bone, called allografts, to stabilize vertebrae, and is used mostly in the lower, or lumbar, spine. The dowels are inserted using an entirely percutaneous or minimally invasive, minimally destructive technique between facet joints in the back to stop movement and pain. The TruFUSE technique is one of the first intermediate surgical options to fill the large void between traditional non-surgical back pain management and major spine fusion surgery. Two dowels are used to fuse one vertebra.

TruFUSE has been used on select patients since March 2006, and went into limited distribution in August 2006. With 30 distributors and over 100 hospital approvals and active surgeons, minSURG is preparing a broad market launch and expects to train and certify an additional 400 to 500 surgeons before the end of the year.

James Doulgeris, MinSURG's president and CEO, said, "TruFUSE represents a new, intermediate surgical option for many chronic back pain sufferers where there was none before. We are strongly encouraged by its rapidly broadening acceptance, particularly by patients, as an endorsement that validates TruFUSE's potential. With experienced management and systems in place to serve a much larger segment of the medical and healthcare community, both here and abroad, we are looking forward to the challenge of growing TruFUSE into a major surgical solution in the coming months."

TruFUSE is used to treat a variety of back problems, including augmentation of other procedures, for any location from C2-C3 to L5-S1. Compared to many existing methods, TruFUSE is generally less invasive, less destructive, less complicated, less expensive and subjects the patients to relatively minimal risk. It is also one of the few surgical options that can supplement or stand alone without precluding other options.

For more information on TruFUSE, please visit the Web site at http://www.trufuse.com or call (813) 318-0565 ext. 216.


'/>"/>
SOURCE Orthopedic Development Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India - Favored Orthopedics Surgery Destination
2. MDCT Compared to Digital Radiography in Orthopedic Patients
3. Drug Eluting Nanostructured Coatings Enable Targeted Drug Therapy for Orthopedic Patients
4. Developmental, neurologic problems common in extremely preterm infants
5. Cancer drugs in development nearly doubled since 1995
6. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
7. Role of zinc in development
8. Particulate matter affects lung development
9. Fossil teeth and human development
10. High development costs hinder entry of cancer super drugs into the market
11. Fireflies help speed development of new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... pluripotent stem (iPS) cells and other difficult to transfect cells, announces its launch ... PluriQ™ G9™ Gene Editing System is a complete system for culturing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology: